[단독] 리가켐 김용주 "ADC 다음 CNS"…승계 뒤에도 R&D 주도

Rigakem Bioscience's strategic shift toward CNS development after ADC success signals a critical pivot to differentiate in an increasingly saturated platform market. By having founder Kim maintain R&D decision-making authority while new leadership assumes operational control, the company introduces a novel succession model that preserves innovation continuity. CNS entry, with higher technical barriers than ADC, offers a defensible competitive advantage against platform replication.